Microbiota, gastrointestinal infections, low-grade inflammation, and antibiotic therapy in irritable bowel syndrome (IBS): an evidence-based review

Revista de Gastroenterología de México (English Edition)

Aurelio López-Colombo¹  María Victoria Bielsa²  Miguel Angel Valdovinos³  Angélica Hernández⁴  Ramón Carmona-Sánchez⁵  José Luis Tamayo⁶  José María Remes-Troche⁷  Max Schmulson⁸  Mario Peláez-Luna⁸  Yolanda López Vidal⁹ 

[1] Coordination of Health Research Delegation, Instituto Mexicano del Seguro Social, Puebla-Pue., Mexico;Department of Gastroenterology, School of Medicine, Universidad Autónoma de Guadalajara, Guadalajara-Jal., Mexico;Department of Gastroenterology. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico;Endoscopy Service, Instituto Nacional de Cancerología. Mexico City, Mexico;Gastroenterology Service, Internal Medicine Service, Hospital Ángeles-CMP, San Luis Potosí-S.L.P., Mexico;Health Sciences Research and Teaching Center, Universidad Autónoma de Sinaloa. Hospital Civil de Culiacán, Culiacán-Sin., Mexico;Laboratory of Digestive Physiology and Gastrointestinal Motility, Medical and Biological Research Institute, Universidad Veracruzana, Veracruz, Veracruz;Laboratory of Liver, Pancreas, and Motility (HIPAM), Department of Experimental Medicine, Universidad Nacional Autónoma de México (UNAM) Hospital General de México, Mexico City, Mexico;Molecular Microbial Immunology Program, Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico;

关键词: Irritable bowel syndrome;    Bacterial overpopulation;    Post-infectious;    Microbiota;    Low-grade inflammation;    Antibiotic treatment;    Rifaximin;    Adults;    Children;    Evidence-based review;    Mexico;   

DOI  :  10.1016/j.rgmxen.2014.01.001

来源: DOAJ

【 授权许可】

Unknown